SEC Form 4
ICU Medical Inc (ICUI) insider trading
In the 12 months to Nov 1, 2026, 7 ICUI insiders reported open-market sales of $8.3M across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $8.3M
- 13 filings · 7 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 3 of 13
- $3.5M of $8.3M sold (43%)
Who traded ICUI, and when
- Sale
- Sale, pre-arranged (10b5-1)
ICUI daily close from Nov 3, 2025 to Oct 30, 2026, between $115.45 and $187.26, last $163.78. 13 sale and 0 purchase filings by 7 insiders, marked at their filing dates. Brian Michael Bonnell, Chief Financial Officer: sold $2.7M across 2 filings, first filed Aug 31, 2026, last Sep 1, 2026. Daniel Woolson, VP, GM-Infusion Capital → President: sold $1.7M across 3 filings, first filed Nov 25, 2025, last Aug 13, 2026. Christian B. Voigtlander, Chief Operating Officer: sold $1.6M across 1 filing, first filed Aug 11, 2026, last Aug 11, 2026. Virginia Ruth Sanzone, VP, General Counsel: sold $1.3M across 3 filings, first filed Nov 12, 2025, last Sep 3, 2026. Ben Sousa, Chief Information Officer: sold $401.2K across 1 filing, first filed Aug 12, 2026, last Aug 12, 2026. David C. Greenberg, Director: sold $297.9K across 1 filing, first filed May 13, 2026, last May 13, 2026. Elisha W. Finney, Director: sold $249.4K across 2 filings, first filed Nov 12, 2025, last Aug 11, 2026.
Largest mark · tap a row for others
Brian Michael Bonnell · Chief Financial Officer
Filing 1 of 2 within a week · $2,724,818 total
Sale $1,608,143
9,307 shares at $172.79 avg
Filed Aug 31, 2026
Pre-arranged (10b5-1) · close on filing date $172.95
Brian Michael Bonnell · Chief Financial Officer
Chief Financial Officer
$2.7M soldDaniel Woolson · VP, GM-Infusion Capital → President
VP, GM-Infusion Capital → President
$1.7M soldChristian B. Voigtlander · Chief Operating Officer
Chief Operating Officer
$1.6M soldVirginia Ruth Sanzone · VP, General Counsel
VP, General Counsel
$1.3M soldBen Sousa · Chief Information Officer
Chief Information Officer
$401.2K soldDavid C. Greenberg · Director
Director
$297.9K soldElisha W. Finney · Director
Director
$249.4K soldOpen-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Brian Michael Bonnell | Chief Financial Officer | $2.7M | — | 2 | 100% of sales | |
| Daniel Woolson | VP, GM-Infusion Capital → President | $1.7M | — | 3 | — | |
| Christian B. Voigtlander | Chief Operating Officer | $1.6M | — | 1 | — | |
| Virginia Ruth Sanzone | VP, General Counsel | $1.3M | — | 3 | 65% of sales | |
| Ben Sousa | Chief Information Officer | $401.2K | — | 1 | — | |
| David C. Greenberg | Director | $297.9K | — | 1 | — | |
| Elisha W. Finney | Director | $249.4K | — | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Virginia Ruth Sanzone VP, General Counsel | SalePre-arranged (10b5-1) | 4,856 | $168.69 | $819.2K | 16,020 | |
traded | Brian Michael Bonnell Chief Financial Officer | SalePre-arranged (10b5-1) | 6,381 | $175.00 | $1.1M | 56,062 | |
traded | Brian Michael Bonnell Chief Financial Officer | SalePre-arranged (10b5-1) | 9,307 | $172.79 | $1.6M | 63,556 | |
traded | Daniel Woolson VP, GM-Infusion Capital | Sale | 5,417 | $181.33 | $982.3K | 17,062 | |
traded | Ben Sousa Chief Information Officer | Sale | 2,250 | $178.32 | $401.2K | 3,076 | |
traded | Elisha W. Finney Director | Sale | 378 | $182.48 | $69.0K | 4,871 | |
traded | Christian B. Voigtlander Chief Operating Officer | Sale | 8,929 | $182.93 | $1.6M | 37,377 | |
traded | Daniel Woolson President | Sale | 2,123 | $132.21 | $280.7K | 22,479 | |
traded | Virginia Ruth Sanzone VP, General Counsel | Sale | 2,447 | $124.08 | $303.6K | 19,460 | |
traded | David C. Greenberg Director | Sale | 2,424 | $122.91 | $297.9K | 7,960 | |
traded | Daniel Woolson VP, GM-Infusion Capital | Sale | 2,897 | $152.35 | $441.4K | 11,297 | |
traded | Elisha W. Finney Director | Sale | 1,285 | $140.42 | $180.4K | 3,995 | |
traded | Virginia Ruth Sanzone VP, General Counsel | Sale | 930 | $142.35 | $132.4K | 5,456 |
GET /stocks/filings/vX/form-4?tickers=ICUI&filing_date.gte=2025-11-01&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ICUI"
],
"issuer_cik": "0000883984",
"owner_cik": "0001669639",
"accession_number": "0001669639-26-000004",
"form_type": "4",
"filing_date": "2026-09-03",
"period_of_report": "2026-09-03",
"issuer_name": "ICU MEDICAL INC/DE",
"issuer_trading_symbol": "ICUI",
"owner_name": "Sanzone Virginia Ruth",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "VP, General Counsel",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 724,
"transaction_price_per_share": 169.5255,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 15296,
"transaction_value": 122736.462,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026."
},
{
"id": "F4",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.5 to $169.665, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."
}
]
},
{
"tickers": [
"ICUI"
],
"issuer_cik": "0000883984",
"owner_cik": "0001669639",
"accession_number": "0001669639-26-000004",
"form_type": "4",
"filing_date": "2026-09-03",
"period_of_report": "2026-09-03",
"issuer_name": "ICU MEDICAL INC/DE",
"issuer_trading_symbol": "ICUI",
"owner_name": "Sanzone Virginia Ruth",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "VP, General Counsel",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2202,
"transaction_price_per_share": 167.667,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 17258,
"transaction_value": 369202.734,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.20 to $168.145, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 59 records
- Option exercises33 records
- Tax withholding25 records
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has ICU Medical Inc's CEO sold stock?
No. Vivek Jain (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is ICUI’s insider data?
These are ICUI Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ICUI insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ICUI every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.